ClinicalTrials.gg
CompletedNCT04083235NAPOLI 3Updated Apr 20, 2026Results posted

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

A Phase 3 interventional study of Irinotecan Liposomal Injection and Oxaliplatin in Metastatic Adenocarcinoma of the Pancreas, sponsored by Ipsen. Completed at 200 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Ipsen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
770
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.

02

Conditions studied

  • Metastatic Adenocarcinoma of the Pancreas
03

In context

Lead sponsor

Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or confirmed adenocarcinoma of the pancreas that has not been previously treated in the setting.
  • Initial diagnosis of metastatic disease must have occurred ≤6 weeks prior to screening.
  • Subject has one or more metastatic lesions measurable by computed tomography (CT) scan (or magnetic resonance imaging (MRI), if the subject is allergic to CT contrast media) according to Version 1.1 criteria.
  • (ECOG) performance status of 0 or 1.
  • Subject has adequate biological parameters as demonstrated by the following blood counts:(a) (ANC) ≥2000/mm3 without the use of hemopoietic growth factors within the last 7 days prior to randomisation (b) count ≥100,000/mm3 (c) (Hgb) ≥9 g/dL obtained ≤14 days prior to randomisation.
  • Adequate hepatic function as evidenced by: (a) Serum total ≤1.5x (biliary drainage is allowed for biliary obstruction), and (b) (AST) and alanine aminotransferase (ALT) ≤2.5x upper limit of normal (ULN) (≤5x ULN is acceptable if liver metastases are present).
  • Adequate renal function as evidenced by ≥30 mL/min.
  • Adequate coagulation studies (obtained ≤14 days prior to randomisation) as demonstrated by and partial thromboplastin time within normal limits (≤1.5xULN ).

Exclusion criteria

Exclusion Criteria:

  • Prior treatment of pancreatic cancer in the setting with surgery, radiotherapy, chemotherapy or therapy
  • Prior treatment of pancreatic adenocarcinoma with chemotherapy in the setting, except those where at least 12 months have elapsed since completion of the last dose and no persistent treatment-related toxicities are present.
  • Subject has only localised advanced disease.
  • Documented serum albumin \<3 g/dL
  • Known history of central nervous system (CNS) metastases.
  • gastrointestinal disorder
  • History of any second in the last 2 years
  • Concurrent illnesses that would be a relative to trial participation
  • Use of strong inhibitors or inducers of , CYP2C8 and UGT1A1
  • Neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
  • Known low or absent dihydropyrimidine dehydrogenase (DPD) activity
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
770 participants (actual)

Study arms

  • Experimental
    Irinotecan liposome injection + Oxaliplatin + 5-FU/LV

    Irinotecan liposome injection, oxaliplatin, 5 FU/LV, will be administered on Days 1 and 15 of each 28-day cycle (until progression or unacceptable toxicity).

    Drug: Irinotecan Liposomal Injection · Drug: Oxaliplatin · Drug: 5Fluorouracil · Drug: Leucovorin

  • Active comparator
    Nab-paclitaxel + Gemcitabine

    Nab-paclitaxel and gemcitabine will be administered on Days 1, 8 and 15 of each 28-day cycle (until progression or unacceptable toxicity).

    Drug: Nab-paclitaxel · Drug: Gemcitabine

Interventions

  • Irinotecan liposome injection is irinotecan in the form of the sucrosofate salt, encapsulated in liposomes for i.v. infusion. It is supplied in sterile, single-use vials containing 10 mL of irinotecan liposome injection at a concentration of 4.3 mg/mL free base equivalent (FBE).

    Also known as: Onivyde®, Nal-IRI

  • Oxaliplatin injection, USP is supplied in single-dose vials containing 50 mg, 100 mg or 200 mg of oxaliplatin as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL.

    Also known as: Eloxatin®

  • Fluorouracil injection, USP is a colorless to faint yellow, aqueous, sterile, nonpyrogenic injectable solution available in 50 mL and 100 mL pharmacy bulk package. Each mL contains 50 mg fluorouracil in water for injection, USP.

    Also known as: Adrucil®, flurouracil, 5-FU

  • Leucovorin Calcium for Injection is supplied in vials ranging from 50-500 mg and available as an injectable solution or lyophilized powder for reconstitution.

    Also known as: Folinic Acid

  • Nab-paclitaxel is a lyophilised powder containing 100 or 250 mg of paclitaxel formulated as albumin-bound particles in single-use vials for re-constitution. Each mL of the reconstituted formulation will contain 5 mg/mL paclitaxel.

    Also known as: Abraxane®

  • Gemcitabine for injection is a lyophilised powder for solution for infusion, with each single use vial containing 200 mg, 1 g or 2 g of gemcitabine.

    Also known as: Gemzar®

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    The OS was defined as time from the date of randomization to the date of death due to any cause. Participants who did not have a date of death recorded at the time of the final analysis were censored at the last known time that the participant was alive. The median OS was measured using Kaplan-Meier technique.

    Time frame: Assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, end of treatment (EoT) visit, then every 2 months thereafter up to primary completion date (PCD) of 23 July 2022 (maximum of 893 days)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from the date of randomization to the first documented disease progression using response evaluation criteria in solid tumors (RECIST) Version 1.1 as per Investigator assessment or death due to any cause. The median PFS was measured using Kaplan-Meier technique.

    Time frame: Assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose up to PCD of 23 July 2022 (maximum of 893 days)

  2. Overall Response Rate (ORR)

    The ORR was defined as the percentage of participants with a best overall response (BOR) characterized as either a complete response (CR) or partial response (PR) per RECIST Version 1.1. BOR was defined as the best response as recorded from randomization until documented objective disease progression using RECIST Version 1.1. As per RECIST version 1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesions; and overall response = CR + PR. The ORR was calculated using Clopper-Pearson method.

    Time frame: Assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose up to PCD of 23 July 2022, (maximum of 893 days)

07

Results

Posted Mar 13, 2024

Participant flow

This Phase 3, open-label study was conducted in participants with metastatic adenocarcinoma of the pancreas at 187 investigational sites in 18 countries (Australia, Brazil, Canada, Israel, Republic of Korea, United States, Austria, Belgium, Czechia, France, Germany, Greece, Hungary, Italy, Portugal, Spain, United Kingdom, and Russia) between 11 February 2020 and 18 February 2025.

Participant flow — Overall Study
MilestoneNALIRIFOXNab-paclitaxel+Gemcitabine
Started383387
Received treatment370379
Completed00
Not completed383387
Withdrew: Death338351
Withdrew: Withdrawal by subject1820
Withdrew: Lost to follow-up21
Withdrew: Progressive disease per recist95
Withdrew: Adverse event58
Withdrew: Switched to commercial drug supply50
Withdrew: Transition to expanded access program10
Withdrew: Protocol violation01
Withdrew: Participant randomized in error01
Withdrew: Physician decision40
Withdrew: Does not meet entry criteria10

Outcome measures

PrimaryOverall Survival (OS)

The OS was defined as time from the date of randomization to the date of death due to any cause. Participants who did not have a date of death recorded at the time of the final analysis were censored at the last known time that the participant was alive. The median OS was measured using Kaplan-Meier technique.

Time frame:
Assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, end of treatment (EoT) visit, then every 2 months thereafter up to primary completion date (PCD) of 23 July 2022 (maximum of 893 days)
Reported as:
Median · months
Overall Survival (OS)
monthsNALIRIFOXNab-paclitaxel+Gemcitabine
Overall Survival (OS)11.1 (10.0 to 12.1)9.2 (8.3 to 10.6)
Statistical analysis
  • NALIRIFOX vs Nab-paclitaxel+Gemcitabine · Stratified log-rank test · p = 0.04 · Hazard ratio (hr): 0.83 · 95% CI 0.70 to 0.99The HR and 95% confidence interval (CI) was based on a stratified Cox proportional hazards regression model, stratified by baseline Eastern Cooperative Oncology Group (ECOG) performance status, region and liver metastases as per IWRS.
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from the date of randomization to the first documented disease progression using response evaluation criteria in solid tumors (RECIST) Version 1.1 as per Investigator assessment or death due to any cause. The median PFS was measured using Kaplan-Meier technique.

Time frame:
Assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose up to PCD of 23 July 2022 (maximum of 893 days)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsNALIRIFOXNab-paclitaxel+Gemcitabine
Progression Free Survival (PFS)7.4 (6.0 to 7.7)5.6 (5.3 to 5.8)
Statistical analysis
  • NALIRIFOX vs Nab-paclitaxel+Gemcitabine · Stratified log-rank test · p = <0.0001 · Hazard ratio (hr): 0.69 · 95% CI 0.58 to 0.83The HR and 95% CI was based on a stratified Cox proportional hazards regression model, stratified by baseline ECOG performance status, region and liver metastases as per IWRS.
SecondaryOverall Response Rate (ORR)

The ORR was defined as the percentage of participants with a best overall response (BOR) characterized as either a complete response (CR) or partial response (PR) per RECIST Version 1.1. BOR was defined as the best response as recorded from randomization until documented objective disease progression using RECIST Version 1.1. As per RECIST version 1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesions; and overall response = CR + PR. The ORR was calculated using Clopper-Pearson method.

Time frame:
Assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose up to PCD of 23 July 2022, (maximum of 893 days)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsNALIRIFOXNab-paclitaxel+Gemcitabine
Overall Response Rate (ORR)41.8 (36.8 to 46.9)36.2 (31.4 to 41.2)
Statistical analysis
  • NALIRIFOX vs Nab-paclitaxel+Gemcitabine · Cochran-Mantel-Haenszel · p = 0.11 · Odds ratio (or): 1.26 · 95% CI 0.95 to 1.69OR, 95% CI and p-value were obtained from the Cochran-Mantel-Haenszel test adjusting by baseline ECOG performance status, region and liver metastases as per IWRS.

Adverse events

Collected over Treatment-emergent serious adverse events (TESAEs) and non-serious TEAEs were collected from the start of study treatment administration (Day 1) up to 30 days after the last dose of study treatment, approximately 1530 days. All-cause mortality (death) was assessed from signing of the informed consent form till end of follow up per participant, approximately 1834 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NALIRIFOX345/370 (93.2%)207/370 (55.9%)364/370 (98.4%)
Nab-paclitaxel+Gemcitabine359/379 (94.7%)198/379 (52.2%)371/379 (97.9%)
Most frequent serious events
Showing 10 of 238
Most frequent serious events
EventNALIRIFOXNab-paclitaxel+Gemcitabine
DiarrhoeaGastrointestinal disorders23/3709/379
VomitingGastrointestinal disorders22/3706/379
NauseaGastrointestinal disorders18/3703/379
COVID-19Infections and infestations18/37017/379
SepsisInfections and infestations6/37016/379
PneumoniaInfections and infestations7/37013/379
PyrexiaGeneral disorders9/37012/379
DehydrationMetabolism and nutrition disorders11/3704/379
Pulmonary embolismRespiratory, thoracic and mediastinal disorders10/3707/379
Abdominal painGastrointestinal disorders9/3708/379
Most frequent other events
Showing 10 of 62
Most frequent other events
EventNALIRIFOXNab-paclitaxel+Gemcitabine
DiarrhoeaGastrointestinal disorders257/370136/379
NauseaGastrointestinal disorders216/370161/379
AnaemiaBlood and lymphatic system disorders97/370153/379
VomitingGastrointestinal disorders140/37095/379
FatigueGeneral disorders121/370143/379
Decreased appetiteMetabolism and nutrition disorders136/370104/379
NeutropeniaBlood and lymphatic system disorders107/370121/379
AlopeciaSkin and subcutaneous tissue disorders53/370119/379
HypokalaemiaMetabolism and nutrition disorders116/37050/379
AstheniaGeneral disorders111/370103/379

Baseline characteristics

The Intent-to-Treat (ITT) population consisted of all randomized participants to whom study treatment was assigned by randomization.

Age, Continuous
Age, Continuous(years)NALIRIFOXNab-paclitaxel+GemcitabineTotal
Mean62.8 ± 9.7164.0 ± 8.3463.4 ± 9.06
Sex: Female, Male
Sex: Female, Male(Participants)NALIRIFOXNab-paclitaxel+GemcitabineTotal
Female179157336
Male204230434
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NALIRIFOXNab-paclitaxel+GemcitabineTotal
Hispanic or Latino493079
Not Hispanic or Latino305328633
Unknown or Not Reported292958
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)NALIRIFOXNab-paclitaxel+GemcitabineTotal
White315324639
Not Reported262955
Asian201838
Black or African American12719
Other7613
Multiple303
American Indian or Alaska Native022
Native Hawaiian or Other Pacific Islander011
08

Study locations

200 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Banner Health- MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Mayo Clinic - Scottsdale
    Phoenix, Arizona 85054, United States
  • Comprehensive Blood And Cancer Center
    Bakersfield, California 93309, United States
  • University of California- Irvine Health Cancer Cente
    Costa Mesa, California 92627, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • University of California, Los Angeles (UCLA)
    Los Angeles, California 90095, United States
  • St. Jude Hospital Yorba Linda dba St. Joseph Heritage Healthcare
    Orange, California 92835, United States
  • University of California - Irvine Medical Center
    Orange, California 92868, United States
  • Torrance Memorial Physician Network Cancer Care
    Redondo Beach, California 90277, United States
  • Sutter Health Sacramento
    Sacramento, California 95816, United States
  • Presbyterian Intercommunity Hospital (PIH)
    Whittier, California 90602, United States
  • UC Health Memorial Hospital
    Colorado Springs, Colorado 80909, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • Miami Cancer Institute
    Miami, Florida 33176, United States
  • Mount Sinai Medical Center of Florida, Inc.
    Miami Beach, Florida 33140, United States
  • Florida Cancer Specialists - Fort Myers
    Sarasota, Florida 34236, United States
  • Florida Cancer Specialists - Panhandle
    Tallahassee, Florida 32308, United States
  • Florida Cancer Specialists - St. Petersburg
    Tampa, Florida 33607, United States
  • Florida Cancer Specialists - East
    West Palm Beach, Florida 33401, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Edward Hospital - Elmhurst
    Elmhurst, Illinois 60540, United States
  • Illinois CancerCare - Peoria
    Peoria, Illinois 61443, United States
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
  • Fort Wayne Medical Oncology and Hematology
    Fort Wayne, Indiana 46804, United States
  • Siouxland Hematology - Oncology Associates, LLP
    Sioux City, Iowa 51101, United States
  • University of Kentucky Markey Cancer Center
    Lexington, Kentucky 40536, United States
  • Pikeville Medical Center
    Pikeville, Kentucky 41501, United States
  • Hematology Oncology Clinic
    Baton Rouge, Louisiana 70809, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Willis-Knighton Cancer Center
    Shreveport, Louisiana 71103, United States
  • Maine Center for Cancer Medicine
    Scarborough, Maine 04074, United States
  • Maryland Oncology Hematology
    Silver Spring, Maryland 20904, United States
  • Beth Israel Deaconess
    Boston, Massachusetts 02215, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Cancer and Hematology Centers of Western Michigan
    Grand Rapids, Michigan 49546, United States
  • Health Partners Institute
    Minneapolis, Minnesota 55425, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55902, United States
  • Research Medical Center
    Kansas City, Missouri 64132, United States
  • Frontier Cancer Center
    Billings, Montana 59102, United States
  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Clinical Research Alliance, Inc
    Lake Success, New York 10021, United States
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
  • Messino Cancer Center
    Asheville, North Carolina 28806, United States
  • The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James)
    Columbus, Ohio 43210, United States
  • Toledo Clinic Cancer Center
    Toledo, Ohio 43623, United States
  • University of Oklahoma - Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Oncology Associates of Oregon
    Eugene, Oregon 97401, United States
  • Compass Oncology - Rose Quarter Cancer Center
    Portland, Oregon 97227, United States
  • Kaiser Permanente - Northwest
    Portland, Oregon 97227, United States
  • Oregon Health & Science University (OHSU)
    Portland, Oregon 97239, United States
  • University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Greenville Hospital System
    Greenville, South Carolina 29605, United States
  • Chattanooga Oncology Hematology Care - Tennessee Oncology
    Chattanooga, Tennessee 37404, United States
  • The West Cancer Center
    Memphis, Tennessee 38138, United States
  • Sarah Cannon and HCA Research Institute
    Nashville, Tennessee 37203, United States
  • Texas Oncology - Austin
    Austin, Texas 78731, United States
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Houston Methodist Research Institute
    Houston, Texas 77030, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Oncology Consultants
    Houston, Texas 77030, United States
  • Texas Oncology - Tyler
    Tyler, Texas 75702, United States
  • Texas Oncology - Wichita Falls
    Wichita Falls, Texas 76310, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84106, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Blue Ridge Cancer Care
    Wytheville, Virginia 24014, United States
  • Froedtert Hospital and the Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Bankstown-Lidcombe Hospital
    Bankstown, 2200, Australia
  • Monash Medical Centre
    Clayton, 3168, Australia
  • Fiona Stanley Hospital
    Murdoch, 6150, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, 6009, Australia
  • St John of God Subiaco Hospital
    Subiaco, 6008, Australia
  • Queen Elizabeth Hospital
    Woodville South, 5011, Australia
  • Medizinische Universitaet Graz
    Graz, 8036, Austria
  • Ordensklinikum Linz GmbH Barmherzige Schwestern
    Linz, 4010, Austria
  • SCRI-CCCIT Gemeinnutzige Gmbh- Gemeinnutzige Salzburger Landeskliniken Betriebsgesmbh
    Salzburg, A-5020, Austria
  • Medical University of Vienna
    Vienna, 1090, Austria
  • Onze-Lieve-Vrouwziekenhuis
    Aalst, 9300, Belgium
  • ASBL Grand Hôpital de Charleroi (GHdC), Site Notre Dame
    Charleroi, 6000, Belgium
  • Universitair Ziekenhuis Antwerpen (UZA)
    Edegem, 2650, Belgium
  • University Hospital Gent
    Ghent, 9000, Belgium
  • Hospital centre Jolimont
    Haine-Saint-Paul, 7100, Belgium
  • University Hospital (UZ) Leuven
    Leuven, 3000, Belgium
  • University Hospital Mont-Godinne
    Yvoir, 5530, Belgium
  • Fundação Pio XII - Hospital de Câncer de Barretos
    Barretos, 14784-400, Brazil
  • Centro Regional Integrado de Oncologia (CRIO)
    Ceará, 60336-550, Brazil
  • Instituto de Oncologia do Parana - IOP
    Curitiba, 80530-010, Brazil
  • Centro de Pesquisas Oncológicas - CEPON
    Florianópolis, 88034-000, Brazil
  • Hospital de Caridade de Ijui
    Ijuí, 98700, Brazil
  • Clinica Neoplasias Litoral
    Itajaí, 88301-220, Brazil
  • Hospital Bruno Born
    Lajeado, 95900, Brazil
  • Centro de Pesquisas Clinicas de Natal - CPCLIN
    Natal, 59025-050, Brazil
  • Irmandade da Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, Brazil
  • Instituto Nacional Do Cancer (INCA)
    Rio de Janeiro, 20230-130, Brazil
  • Instituto COI
    Rio de Janeiro, 22793-080, Brazil

Showing the first 100 of 200 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Abdelrahim M, Khan G, Hatoum H, Zervoudakis A, Dayyani F, Zhang L, Li J, Maxwell F, O'Reilly EM, Wainberg ZA, Bullock A. Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. Future Oncol. 2026 May;22(12):1421-1428. doi: 10.1080/14796694.2026.2664776. Epub 2026 May 4. PubMed 42080361 ↗
  • Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardiere C, Dean A, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab T, Pant S, Hubner RA, Xiao Z, Chen H, Benzaghou F, O'Reilly EM. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023 Oct 7;402(10409):1272-1281. doi: 10.1016/S0140-6736(23)01366-1. Epub 2023 Sep 11. PubMed 37708904 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the United States (US) and/or Europe (EU).

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Jul 2022, 29 months.

Results were first posted in Mar 2024, 1 year 7 months after primary completion. A results delay was requested in Jul 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2019
First posted
Sep 10, 2019
StartActual
Feb 11, 2020
Primary completionActual
Jul 23, 2022
CompletionActual
Feb 18, 2025
Results delay requested
Jul 18, 2023
Results first posted
Mar 13, 2024
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04083235
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Sep 10, 2019
Start date
Feb 11, 2020
Primary completion
Jul 23, 2022
Completion
Feb 18, 2025
Results posted
Mar 13, 2024
Last update
Apr 20, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxaliplatin · Fluorouracil · Leucovorin

Start the discussion